Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

InMed Pharmaceuticals (INM) Shares Outstanding (Weighted Average) (2021 - 2025)

Historic Shares Outstanding (Weighted Average) for InMed Pharmaceuticals (INM) over the last 4 years, with Q3 2025 value amounting to $4.0 million.

  • InMed Pharmaceuticals' Shares Outstanding (Weighted Average) rose 53769.99% to $4.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $4.0 million, marking a year-over-year increase of 53769.99%. This contributed to the annual value of $975985.0 for FY2025, which is 15612.84% up from last year.
  • According to the latest figures from Q3 2025, InMed Pharmaceuticals' Shares Outstanding (Weighted Average) is $4.0 million, which was up 53769.99% from $975985.0 recorded in Q2 2025.
  • InMed Pharmaceuticals' Shares Outstanding (Weighted Average)'s 5-year high stood at $4.0 million during Q3 2025, with a 5-year trough of $166410.0 in Q3 2023.
  • For the 4-year period, InMed Pharmaceuticals' Shares Outstanding (Weighted Average) averaged around $1.1 million, with its median value being $620127.0 (2024).
  • As far as peak fluctuations go, InMed Pharmaceuticals' Shares Outstanding (Weighted Average) plummeted by 8443.7% in 2024, and later surged by 53769.99% in 2025.
  • Quarter analysis of 4 years shows InMed Pharmaceuticals' Shares Outstanding (Weighted Average) stood at $566062.0 in 2022, then decreased by 29.57% to $398673.0 in 2023, then soared by 77.22% to $706546.0 in 2024, then skyrocketed by 459.7% to $4.0 million in 2025.
  • Its Shares Outstanding (Weighted Average) was $4.0 million in Q3 2025, compared to $975985.0 in Q2 2025 and $1.1 million in Q1 2025.